MedTrace Logo

Analysis of the Prognostic Role of Epigenetic Biomarkers in Relation to the Motor Decline in Parkinson's Disease

NCT05384522 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 103

Last updated 2024-03-05

No results posted yet for this study

Summary

BioGenParkinson is an observational, prospective cohort study evaluating biomarkers of Parkinson's Disease (PD) progression in community-dwelling subjects aged 65 years or more, consecutively referring to INRCA outpatient clinic of the Neurology Unit. Selected patients will undergo clinical and laboratory evaluations at the baseline, and will be followed up after 6 and 12 months. The biological evaluation will include the determination of i) routine biological parameters ii) advanced biomarkers such as epigenetic analysis of DNA methylation, genetic analysis on multiple loci associated with PD progression and specific proteins associated with motor and non-motor decline. After obtaining all data, multiple statistical analysis will be performed to evaluate the most accurate prognostic biomarkers of PD progression at this stage of disease.

Conditions

  • Parkinson Disease

Interventions

OTHER

blood samples collection

Blood samples will be drawn at baseline and at 6 and 12 months from baseline

Sponsors & Collaborators

  • Istituto Nazionale di Ricovero e Cura per Anziani

    lead OTHER

Principal Investigators

  • Giuseppe Pelliccioni, MD · IRCCS INRCA, Ancona, Italy

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-30
Primary Completion
2026-01-30
Completion
2026-01-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05384522 on ClinicalTrials.gov